Each row below is one compound's US status as its own reptides page states it, word for word, with the sources that page cites and the date they were last checked. 277 of the 310 compounds this site covers have a page section that states their status; the other 33 are named after the table, with no sourced status section yet.
The rows report US federal status, mostly FDA approval and, for a few compounds, a controlled-substance schedule, along with the World Anti-Doping Agency's prohibited list where a page cites it. Where a page also names another country's approval or rules, its row keeps them. US state rules are not covered. This page is published for research reference. It is not legal advice or medical advice.
the table
status by compound
| compound | status, as its page states it | sources | checked |
|---|---|---|---|
| 1,4-DMAA | Was it approved for human use? The 2018 authors reported that 1,4-DMAA had not been approved for human consumption when they conducted the investigation. | ||
| 2,4-dinitrophenol (DNP) | Is DNP approved as a drug or lawful to sell for weight loss? FDA has never approved DNP as a drug, and U.S. enforcement has treated sales for human weight loss as unlawful unapproved or misbranded drug distribution. Rules for possessing or handling the industrial chemical depend on the jurisdiction. | ||
| 3,5-diiodo-L-thyronine (T2) | What is 3,5-diiodothyronine, and is it approved? 3,5-diiodo-L-thyronine (T2) has no FDA application, while T3 (liothyronine, CYTOMEL) has been an approved prescription medicine since 1956. A product labeled only 'T2' does not say which isomer it contains. | ||
| 7,8-Dihydroxyflavone | What is 7,8-dihydroxyflavone, and is it approved? 7,8-Dihydroxyflavone is a small-molecule flavone sold as a research chemical. No FDA application, label or registered study was found, and no record reviewed reports giving it to people. | ||
| 9-Me-BC (9-methyl-beta-carboline) | What is 9-Me-BC, and what is its regulatory status? 9-Me-BC is 9-methyl-beta-carboline, also called 9-methylnorharman, a defined molecule (PubChem CID 164979). It has no label, no application and no registered study in the records reviewed, and it is a separate molecule from other methylated beta-carbolines such as 9-methyl-harmane. | ||
| Abaloparatide | Who does the current US label actually cover? The label covers postmenopausal women and men with osteoporosis who are at high fracture risk, or who failed or could not tolerate another available osteoporosis therapy. Its wording differs by sex: it says abaloparatide reduces vertebral and nonvertebral fracture risk in postmenopausal women, while the male indication is to increase bone density. | ||
| AC-262536 | What is AC-262536, and what is its regulatory status? AC-262536 is a non-steroidal selective androgen receptor modulator, not a steroid and not a testosterone derivative. It has no FDA match or label, and WADA's 2026 list bans selective androgen receptor modulators as a class. | ||
| ACCG-2671 | What is ACCG-2671, and is it approved? ACCG-2671 is Structure Therapeutics' investigational oral, non-peptide, small-molecule dual amylin and calcitonin receptor agonist. FDA database searches on 10 October 2026 found no application or label, and its structure is not disclosed. |
| |
| ACD856 | What is ACD856, and is it approved? ACD856 is an investigational Trk receptor modulator with no FDA approval record, and no public chemical record gives its structure. An openFDA query for ACD856 returned no application on 9 October 2026. | ||
| ACE-031 | What is ACE-031, and has anyone approved it? ACE-031 (ramatercept) is a dimeric fusion protein of the human activin receptor type IIB extracellular domain and the Fc part of human IgG1, not a peptide. It has never been approved: Drugs@FDA queries on 9 October 2026 returned no matching application. | ||
| ACP-105 | What is ACP-105, and what is its regulatory status? ACP-105 is a non-steroidal selective androgen receptor modulator (SARM) from ACADIA Pharmaceuticals. It has no FDA match or label, and WADA's 2026 list prohibits SARMs as a class at all times. | ||
| Adamax | Does New Zealand prescription classification mean Adamax is approved? New Zealand classified the relevant ACTH-analogue group as prescription medicines to control supply. That classification is not marketing authorization and gives Adamax no approved indication or product-specific authorization. | ||
| Adipotide | What is adipotide, and is it an approved drug? Adipotide is a synthetic peptide that joins a fat-vessel homing sequence to a D-amino-acid proapoptotic sequence. On 10 October 2026, openFDA Drugs@FDA returned no match and DailyMed returned no label, so no FDA-approved adipotide product was found. | ||
| Afimoxifene (4-hydroxytamoxifen) | What is afimoxifene, and has anyone approved it? Afimoxifene is 4-hydroxytamoxifen, the estrogen receptor antagonist metabolite of tamoxifen. No FDA approval was found: openFDA and DailyMed returned no record on 10 October 2026, and a 2005 review calls 4-hydroxytamoxifen for gynecomastia investigational. | ||
| Agomelatine | Where is agomelatine approved, and for what? Agomelatine is authorized in the EU for major depressive episodes in adults (Valdoxan, since 19 February 2009), after an earlier refusal for insufficiently shown effectiveness. No FDA-approved agomelatine product was located. | ||
| AHK-Cu | Is AHK-Cu an approved hair-loss drug? FDA and ClinicalTrials.gov records contain no approved AHK-Cu hair-loss drug or exact registered intervention trial. Cosmetic ingredient availability is not drug approval. | ||
| AICAR (acadesine) | What is AICAR, and is it the same as acadesine? Two molecules share the name. Acadesine (AICA riboside) is the nucleoside given in every human study cited, and AICA ribonucleotide (ZMP) is the phosphorylated form made inside cells. An openFDA query on 9 October 2026 returned no application for either. | ||
| Aleniglipron | What is aleniglipron, and is it approved anywhere? Aleniglipron (code GSBR-1290) is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Structure Therapeutics through its subsidiary Gasherbrum Bio. It is not approved: no FDA application record or label turned up on 10 October 2026, and no approval appears in any source reviewed. | ||
| Alpha-GPC | What is Alpha-GPC, and where is it used as a medicine? Alpha-GPC is L-alpha-glycerylphosphorylcholine, also called choline alfoscerate. It supplies choline and glycerophosphate. Italy, Poland and Russia list nationally authorized or registered medicines, while the US GSRS record establishes identity rather than FDA approval. Oral supplements and registered injectable medicines are not interchangeable. | ||
| Amlexanox | What is amlexanox, and what was it approved for? FDA approved APHTHASOL (amlexanox 5% oral paste) for aphthous ulcers on 17 December 1996, and a 2 mg topical patch on 29 September 2004. Both products are listed as discontinued. |
| |
| Amycretin | What is amycretin, and is it approved? Amycretin, now named zenagamtide, is an investigational Novo Nordisk peptide that activates GLP-1 and amylin receptors. openFDA Drugs@FDA returned no record and DailyMed no label for either name on 10 October 2026. The EMA was not searched. |
| |
| Anamorelin | What is anamorelin, and where is it approved? Anamorelin is a small, orally active non-peptide ghrelin receptor agonist. Ono Pharmaceutical said in a company statement dated 22 January 2021 that it received approval in Japan for Adlumiz for cancer cachexia in four cancer types. The EMA refused authorization in 2017, and openFDA and DailyMed returned no US record or label on 10 October 2026. |
| |
| Anastrozole | What is anastrozole approved to do? FDA approved ARIMIDEX (anastrozole) on 27 December 1995. It is labeled only for hormone receptor-positive or unknown breast cancer in postmenopausal women, so use in men for estrogen control is not a labeled use. | ||
| Andarine | What is andarine, and what is its regulatory status? Andarine (S-4, GTx-007) is an arylpropionamide selective androgen receptor modulator (SARM). It has no FDA match or label, and the WADA 2026 list names it explicitly as prohibited at all times. | ||
| aniracetam | Is aniracetam FDA approved? No. FDA names aniracetam among unapproved drugs involved in a US distribution-enforcement case. Online sale does not authenticate the product or create an approved cognitive indication. | ||
| AOD9604 | Is AOD9604 FDA approved or FDA-GRAS? FDA approval records contain no AOD9604 drug. The FDA GRAS Notice Inventory contains no AOD9604 notice or response letter. A private self-affirmed food-use conclusion would not approve injection or disease treatment. WADA prohibits GH fragments. | ||
| armodafinil | How is armodafinil related to modafinil? Armodafinil is the isolated R enantiomer of modafinil and a separate US Schedule IV prescription drug. | ||
| ATX-304 (formerly O304) | Is ATX-304 approved or available as a medicine? FDA approval records contained no exact-name ATX-304 or O304 entry. The 2026 human report is a conference abstract, and the developer says larger phase 2 studies are planned. | ||
| AZD6234 | What is AZD6234, and is it approved? AZD6234 is AstraZeneca's weekly injectable amylin receptor agonist, which the company calls selective. It has no approval record: FDA database searches on 10 October 2026 found no application or label, and no structure is public. | ||
| B7-33 | What is B7-33, and is it approved for anything? B7-33 is a single-chain peptide analogue of human relaxin-2. No approval for any use appears in the records reviewed, and PubChem returned no compound record for it on 9 October 2026, so a vial labeled B7-33 cannot be matched to a public chemical record by name alone. | ||
| Bemethyl | What is bemethyl, and what is its regulatory status? Bemethyl (bemitil, 2-(ethylthio)benzimidazole) is registered in Russia as Metaprot capsules for raising work capacity and adaptation to extreme conditions. No FDA-approved product or registered trial turned up, and a Russian registration is not an FDA or EMA review. | ||
| Berberine | What is berberine, and is it an approved drug? Berberine is a quaternary cation sold as salts such as the hydrochloride, and dihydroberberine is a separate, reduced compound. On 11 October 2026 no FDA-approved berberine drug was found; the one DailyMed listing is a bulk-ingredient entry with no indication or dosing. | ||
| Berobenatide | What is berobenatide, and is it approved anywhere? Berobenatide is the WHO Proposed INN for an exendin-4 derivative carrying a fatty-diacid group, and it is one molecule with MET-097i, MET097 and PF-08653944. Pfizer acquired it with Metsera on 13 November 2025. No regulatory approval was found: openFDA and DailyMed searches on 10 October 2026 returned no application records and no labels. |
| |
| Bimagrumab | Is bimagrumab approved for obesity? FDA Drugs@FDA and Purple Book records contained no exact-name bimagrumab approval. BELIEVE was a phase 2 trial, so its results support development rather than prescribing an approved obesity product. | ||
| BPAP (benzofuranylpropylaminopentane) | What is BPAP, and what is its regulatory status? BPAP here means benzofuranylpropylaminopentane, a deprenyl-derived research compound, usually the R-(-) enantiomer. The acronym is also bisphenol AP, a plastics chemical, and bilevel positive airway pressure, a breathing treatment. No label, application or registered study exists for the compound. | ||
| BPC-157 | Is BPC-157 legal, FDA approved or allowed in sport? On July 23, 2026, FDA’s advisory committee voted to recommend BPC-157 for the 503A compounding list. That recommendation did not grant FDA drug approval. WADA prohibits BPC-157 for covered athletes. As of October 24, 2026, FDA had posted the meeting’s briefing documents, agenda, roster and presentations but no minutes, so the reported vote count rests on news coverage. This answer reports US federal regulatory status and the WADA rule as of that date; it is a research reference and gives no legal advice. | ||
| Brenipatide | Is brenipatide an approved medicine? The cited FDA records list no approval or prescribing label for brenipatide or LY3537031. It remains an investigational drug used in registered studies. | ||
| Bronchogen | What is Bronchogen, and is it an approved drug? Bronchogen is a synthetic tetrapeptide from the Khavinson group, listed in PubChem as Ala-Glu-Asp-Leu, though some of the group's papers print Ala-Asp-Glu-Leu. An openFDA Drugs@FDA query and a DailyMed search on 10 October 2026 found no FDA record for it, so it is not an FDA-approved drug or a labeled product. | ||
| Cabergoline | What is cabergoline approved to do? FDA approved DOSTINEX (cabergoline) on 23 December 1996 for hyperprolactinemic disorders, idiopathic or due to pituitary adenomas, in adults. Prolactin control alongside steroids and use for libido or orgasm fall outside that labeled population. | ||
| cagrilintide | Is cagrilintide FDA approved as a standalone medicine? FDA Drugs@FDA and openFDA records contained no exact-name cagrilintide standalone approval. Cagrilintide remains investigational as monotherapy even though it has been tested in phase 3 as a component arm. | ||
| CagriSema | Is CagriSema approved or still under review? Novo Nordisk says it submitted CagriSema for U.S. approval in December 2025. FDA Drugs@FDA and openFDA records contained no exact-name approval, so approval timing remains unknown. | ||
| Calcium alpha-ketoglutarate | What is calcium alpha-ketoglutarate, and is it an approved drug? Ca-AKG is the calcium salt of alpha-ketoglutarate, a Krebs cycle intermediate the body makes. On 11 October 2026 no FDA-approved Ca-AKG drug was found. The products studied differ: a calcium salt in mouse feed, a delayed-release Ca-AKG and vitamin formulation (Rejuvant), and sustained-release Ca-AKG in the ABLE trial. | ||
| Capromorelin | What is capromorelin, and who has approved it? Capromorelin is an oral ghrelin receptor agonist. FDA has approved it only for animals: ENTYCE for appetite stimulation in dogs (2016) and ELURA for weight loss in cats with chronic kidney disease (2020). A search on 9 October 2026 found no human drug application and no ClinicalTrials.gov record. |
| |
| Cardarine | Is Cardarine FDA approved, still in development, or allowed in tested sport? There is no FDA-approved Cardarine product. WADA says the development program was terminated after serious preclinical toxicities, and the 2026 Prohibited List names GW1516 and GW501516 as PPAR-delta agonist metabolic modulators prohibited at all times. | ||
| Cardiogen | What is Cardiogen, and is it an approved drug? Cardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR) from the Khavinson group. It is not an approved drug: openFDA Drugs@FDA lists no peptide product under the name. Other products share the name, so the sequence has to stay next to it. | ||
| Cartalax | Is Cartalax approved? FDA and ClinicalTrials.gov records contain no approved Cartalax drug, prescribing label, or registered human intervention trial. A patent grants intellectual-property rights; it does not approve a medicine. | ||
| CE-123 | What is CE-123, and what is its regulatory status? CE-123 is a research code for a thiazole analogue of modafinil, 5-(benzhydrylsulfinylmethyl)-1,3-thiazole, studied mostly as the (S)-enantiomer. No label, application or registered study exists, and the neighboring codes CE-103, CE-104, CE-125 and CE-158 are different molecules. | ||
| Cerebrolysin | Where is Cerebrolysin authorized? A CTIS record identifies a Romanian national marketing authorization and an active academic trial. The cited U.S. FDA records list no approved-drug application for Cerebrolysin. A national authorization should not be generalized into approval everywhere. | ||
| Chonluten | What is Chonluten, and is it an approved drug? Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG), also coded T-34, from the Khavinson group. PubChem has no record under the name, so the name is tied to the sequence by the literature. openFDA Drugs@FDA and DailyMed return no product under the name, so no FDA record of it was found. |
| |
| Cibinetide | Is cibinetide FDA approved, and did it reach phase 3? U.S. FDA and ClinicalTrials.gov records listed no approved cibinetide or ARA-290 product and no phase 3 trial. An EU orphan designation for sarcoidosis exists, but orphan designation is a development incentive rather than marketing authorization. | ||
| Citicoline | What is citicoline, and is it an approved drug? Citicoline (CDP-choline) is a molecule the body makes itself. An openFDA query on 9 October 2026 found no FDA-approved citicoline drug. Trial authors state it is approved as a drug in some other countries, but those statements are not regulator records. |
| |
| CJC-1295 | Is CJC-1295 FDA approved or allowed in tested sport? FDA approval records contain no CJC-1295 product. FDA continues to list compounding safety concerns, and GHRH analogues are prohibited for athletes covered by WADA rules. | ||
| cjc+ipa blend | Does compounding make it an FDA-approved treatment? A compounded combination does not acquire FDA approval from its ingredients, its prescriber or its pharmacy. A supplier also needs to establish the exact CJC form, amount of each ingredient and the finished preparation’s quality. None of those checks is a substitute for a clinical trial. | ||
| CL-316243 | What is CL-316243, and is it approved? CL-316243 is a beta-3 adrenoceptor agonist research chemical with no FDA application. Mirabegron, another beta-3 agonist, was approved for overactive bladder in 2012, not for fat loss. | ||
| Clascoterone | What is clascoterone approved to do? FDA approved WINLEVI (clascoterone) cream 1% on 26 August 2020 for acne vulgaris in patients 12 and older, and the European Commission authorized it on 17 October 2025. Neither approval covers hair loss. | ||
| Clenbuterol | Is clenbuterol an FDA-approved human medicine? FDA lists no approved human use in the United States. Ventipulmin is a restricted US horse product whose label says it is not for humans. A 2023 EMA document listed national human products in Bulgaria, Germany, and Italy; those listings were country-level, not centralized EU authorization. | ||
| Clomiphene | What is clomiphene FDA approved to treat? Its US indication is selected ovulatory dysfunction in women who want pregnancy after appropriate evaluation. Male hypogonadism, male infertility, post-AAS recovery, and enhancement are off-label uses. The male evidence has to stand on its own outcomes. | ||
| Clonidine | What is clonidine approved to do? Clonidine hydrochloride tablets are FDA-labeled for hypertension. ONYDA XR, an extended-release oral suspension approved on 24 May 2024, is labeled for ADHD in children 6 and older, alone or as an add-on to stimulants. Stimulant comedown in adults is not a labeled use. |
| |
| CMS-121 (CMS121) | What is CMS-121, and what is its regulatory status? CMS-121 is a research compound, PubChem CID 135741221, that its developers describe as a fisetin derivative; its structure is a quinoline with a catechol ring, not the flavonol fisetin. It has no FDA label, and ClinicalTrials.gov lists one completed Phase 1 trial in healthy volunteers with no posted results. | ||
| Coenzyme Q10 | What is coenzyme Q10, and is it an approved drug? Coenzyme Q10 (ubidecarenone) is the oxidized form, and ubiquinol is the reduced form. An openFDA query on 9 October 2026 found no FDA application, so no FDA-approved CoQ10 drug was located. | ||
| Cortagen | What is Cortagen, and is it an approved drug? Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro (AEDP) from the Khavinson group, made from an analysis of Cortexin, a different brain extract product. openFDA Drugs@FDA and DailyMed return no product under the name, so no FDA record of it was found. | ||
| Cortexin | What is Cortexin, and is it approved? Cortexin is a Russian prescription mixture of water-soluble polypeptide fractions from cattle cerebral cortex, with no single formula. It has no US label; a Russian label lists it for add-on use in stroke, brain injury and other conditions. |
| |
| Crystagen | What is Crystagen, and is it an approved drug? Crystagen is a trade name that the Khavinson group's 2022 table links to the tripeptide Glu-Asp-Pro (EDP), and the table lists it as an immunoprotector. PubChem has no record under the name. ClinicalTrials.gov returned no study, and openFDA Drugs@FDA and DailyMed return no product under the name, so no FDA record was found. | ||
| DADA | What is DADA, and is it approved? DADA is diisopropylammonium dichloroacetate, a salt of dichloroacetic acid with diisopropylamine. It shares only its anion with the sodium dichloroacetate used in nearly all clinical dichloroacetate research. No dichloroacetate salt appears in Drugs@FDA as an approved active ingredient, and DailyMed returned no dichloroacetate label on 9 October 2026. | ||
| Dalosirvat (SM04554) | What is dalosirvat (SM04554), and has anyone approved it? SM04554 is dalosirvat, a topical Wnt activator tested for androgenetic alopecia by Samumed, now Biosplice. No approval was found: openFDA returned no record and DailyMed no label for dalosirvat on 10 October 2026. | ||
| Dapiglutide | What is dapiglutide, and is it approved anywhere? Dapiglutide (ZP7570) is Zealand Pharma's investigational lipidated peptide, described as a dual GLP-1 and GLP-2 receptor agonist. No approval exists: openFDA and DailyMed searches on 10 October 2026 returned no application records and no labels. | ||
| Dasatinib plus quercetin | What is dasatinib plus quercetin, and what is approved? Dasatinib plus quercetin (D+Q) is two separate agents, not one product. Dasatinib is an FDA-approved prescription kinase inhibitor for Philadelphia chromosome-positive leukemia, first approved in 2006, and quercetin is a flavonol supplement. The combination is not approved for any use, and nothing in the dasatinib label covers senescence or aging. | ||
| DHEA | What is DHEA, and what has FDA approved? DHEA (prasterone) is an adrenal steroid precursor. FDA approved a vaginal prasterone insert, INTRAROSA, in 2016 for menopausal dyspareunia, and an openFDA query located no oral or systemic DHEA drug. | ||
| dihexa | Does an FDA substance record mean it is approved? No. FDA explicitly states that having a UNII substance identifier does not imply regulatory review or approval. | ||
| Dihydroboldenone (1-testosterone) | What is dihydroboldenone, and is it the same as boldenone? Dihydroboldenone, sold as DHB, is the chemical 1-testosterone. It is not boldenone, and DHB in chemistry most commonly means 2,5-dihydroxybenzoic acid, an unrelated compound. 1-Testosterone is a Schedule III controlled substance with no approval in any species. | ||
| DNSP-11 | What is DNSP-11, and is it approved for anything? DNSP-11 is an 11-amino-acid amidated peptide from the proregion of the GDNF proprotein. No approval for any use appears in the records reviewed, and PubChem returned no compound record for it on 9 October 2026. | ||
| Drostanolone | What happened to Drolban in the US? FDA’s application review records withdrawal of Drolban’s approval effective March 2, 1994. | ||
| DSIP | Is DSIP an approved sleep treatment? FDA approval records contain no DSIP or emideltide drug. FDA staff recommended against 503A bulks-list inclusion in July 2026; the advisory review did not approve it. | ||
| Dulaglutide | What is dulaglutide approved to do? FDA labels TRULICITY as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Weight management is not a labeled indication. | ||
| Dutasteride | Is this a BPH question, an oral hair-loss question, or a formulation question? US Avodart is approved for symptomatic BPH in men with an enlarged prostate. Oral use for male androgenetic alopecia has randomized evidence but remains off-label in the United States. Topical and scalp-injection products have their own early evidence and cannot borrow Avodart’s approval or pharmacokinetics. | ||
| Ecnoglutide | What is ecnoglutide, and is it approved anywhere? Ecnoglutide (code XW003) is a once-weekly injectable GLP-1 receptor agonist from Hangzhou Sciwind Biosciences. A journal review and company statements say China approved it in January 2026 for type 2 diabetes and in March 2026 for weight management. No FDA application record or label turned up on 10 October 2026. | ||
| Efinopegdutide | What is efinopegdutide, and is it approved anywhere? Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is a once-weekly GLP-1 and glucagon receptor dual agonist that Merck licensed from Hanmi in 2020. It is not approved: no FDA application record or label turned up on 10 October 2026, and PubChem has no compound record, so no formula or CAS number is established. | ||
| Elecoglipron | What is elecoglipron, and is it approved anywhere? Elecoglipron (AZD5004, ECC5004) is an oral small-molecule GLP-1 receptor agonist developed by AstraZeneca under a 2023 license from Eccogene. It is not approved: no FDA application record or label turned up on 10 October 2026, and no approval appears in any source reviewed. |
| |
| eloralintide | Is eloralintide approved, and what human results are available? Eloralintide remains investigational. One peer-reviewed 263-person phase 2 efficacy trial has reported 48-week weight results; registered phase 3 ENLIGHTEN studies have not yet supplied efficacy outcomes. | ||
| Emoxypine succinate | What is emoxypine succinate, and where is it registered? Emoxypine succinate is sold as Mexidol, a Russian prescription medicine. No FDA-approved product turned up, and a Russian registration is not an FDA or EMA review. | ||
| Empagliflozin | What is empagliflozin approved to do? FDA approved empagliflozin as JARDIANCE in 2014. It is labeled for heart failure, chronic kidney disease, cardiovascular death in type 2 diabetes with cardiovascular disease, and glycemic control in type 2 diabetes. None of the four uses relates to anabolic-androgenic steroids. | ||
| Enclomiphene | Is enclomiphene FDA approved? No. The U.S. application received a complete response letter in 2015, and FDA Drugs@FDA and openFDA records contained no exact-name approval. A later compounding advisory discussion did not create an approved drug. | ||
| Endoxifen | What is endoxifen, and has anyone approved it? Endoxifen is a tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen. No FDA approval was found on 10 October 2026, and a 2023 commentary shows an Indian approval exists for acute mania in adults. | ||
| Enicepatide | What is enicepatide, and is it approved anywhere? Enicepatide is the WHO Proposed INN for a synthetic peptide described as a dual GIP and GLP-1 receptor agonist, and it is the same compound as CT-388, developed by Roche. No regulatory approval was found: openFDA and DailyMed searches on 10 October 2026 returned no application records and no labels. |
| |
| Enobosarm | Is enobosarm approved or permitted in sport? FDA approval records contain no enobosarm product. FDA treats marketed SARM products as unapproved drugs, and WADA prohibits enobosarm for covered athletes. | ||
| Epithalon | Is Epithalon FDA approved? FDA approval records contain no Epithalon or Epitalon drug. FDA lists safety concerns for compounded use and does not provide an approved indication or dosing label. FDA staff recommended against 503A bulks-list inclusion when FDA's Pharmacy Compounding Advisory Committee discussed Epitalon on July 24, 2026; the committee's recommendations are non-binding, and FDA had posted no final decision as of October 25, 2026. | ||
| Eplerenone | What is eplerenone approved to do? FDA approved eplerenone as INSPRA on 27 September 2002. The label covers improving survival in stable adults with symptomatic heart failure and an ejection fraction of 40% or less after a heart attack, and treating hypertension in adults. | ||
| Estradiol | What is estradiol used for? Prescription estradiol treats menopausal symptoms and specific causes of estrogen deficiency. Some products are also approved to prevent osteoporosis in selected postmenopausal women. The indication and formulation determine which dosing instructions and safety data apply. | ||
| Exemestane | What is exemestane approved to do? FDA approved AROMASIN (exemestane) on 21 October 1999 for postmenopausal women with estrogen-receptor-positive breast cancer. Use in men is not a labeled use. | ||
| Exenatide | What is exenatide approved to do? FDA approved exenatide as BYETTA in 2005 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. It is not labeled for weight loss or obesity. | ||
| Ezetimibe | What is ezetimibe approved to do? FDA approved ezetimibe as ZETIA on 25 October 2002, as an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia, with a statin or alone when additional LDL-C-lowering therapy is not possible. It has further labeled uses in familial hypercholesterolemia, mixed hyperlipidemia and sitosterolemia. | ||
| Fenbendazole | What is fenbendazole, and what is its regulatory status? Fenbendazole is a benzimidazole carbamate anthelmintic. FDA approves it as an animal drug for dogs, cattle and goats, and it is not approved for use in people. | ||
| FGL peptide | What is FGL, and is it approved for anything? FGL is a synthetic 15-amino-acid peptide that matches the binding site of the neural cell adhesion molecule (NCAM) for fibroblast growth factor receptor 1. No approval for any use appears in the records reviewed. | ||
| Finasteride | Does a compounded topical product inherit Propecia's approval? No. FDA states that no topical finasteride formulation is FDA approved. Compounded products do not have FDA-approved labeling and were not reviewed for safety, effectiveness, or quality before marketing. Skin absorption into the bloodstream is expected, so topical does not mean scalp-only. | ||
| Fisetin | What is fisetin, and is it approved? Fisetin is a plant flavonol sold as a supplement for senolytic and healthy-aging claims. On 11 October 2026, Drugs@FDA and DailyMed searches found no fisetin drug or label, so no FDA-approved fisetin product turned up. Products differ, so no trial result transfers to another product or dose. | ||
| FLGR242 | Does FLGR242 have a 19-day half-life or an approval? The cited U.S. records contain no compound-specific pharmacokinetic curve or exact-name approval entry. The 19-day figure is a seller claim. WADA’s S0 category prohibits non-approved substances, and the claimed myostatin-modulating action may also fall under S4.3 if confirmed. | ||
| Fluoxymesterone | What is fluoxymesterone, and is it still approved? FDA approved fluoxymesterone as HALOTESTIN on 15 October 1956. Approval of the HALOTESTIN application was withdrawn effective 18 June 2009, and every product in the FDA record is marked discontinued. |
| |
| Follistatin-344 | Is Follistatin-344 approved? FDA approval records contain no Follistatin-344 protein product or prescribing label. Investigational AAV trials do not approve a protein vial, and WADA prohibits myostatin-function modifiers for covered athletes. | ||
| FOXO4-DRI | What is FOXO4-DRI, and is it approved for anything? FOXO4-DRI is a D-retro-inverso peptide, built from D-amino acids in reversed sequence, designed to disrupt the interaction of FOXO4 with p53. No approval for any use appears in the records reviewed, and ClinicalTrials.gov queries on 9 October 2026 returned no studies. | ||
| GB-115 (Ranquilon) | What is GB-115, and what is its regulatory status? GB-115 is N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, a dipeptide-like retroanalogue of cholecystokinin-4 designed at the Zakusov Institute of Pharmacology in Moscow and called Ranquilon in Russia. It has no FDA label, and Russian secondary pages describe a Valenta Pharm tablet launched in December 2024 without showing a registration number, so registration in Russia is not established here. | ||
| GHK-Cu | Is GHK-Cu FDA approved? No FDA-approved GHK-Cu drug was identified. FDA’s 503A list treats non-injectable GHK-Cu as a nominated substance under evaluation, while the injectable nomination was withdrawn and injectable GHK-Cu remains on FDA’s safety-risk page. | ||
| GHRP-2 | Where is GHRP-2 approved? Japan has an approved pralmorelin diagnostic injection. No FDA-approved GHRP-2 drug was identified in the United States. WADA prohibits growth-hormone secretagogues for covered athletes. | ||
| GHRP-6 | Is GHRP-6 FDA approved? No FDA-approved GHRP-6 drug was identified. FDA lists compounding safety concerns, and WADA prohibits growth-hormone secretagogues for covered athletes. | ||
| Glutathione | Is injectable glutathione approved for skin lightening or wellness? The cited FDA records list no approved injectable glutathione indication for skin lightening or wellness. Category 1 under the 503A nomination process means evaluation is pending, not approval. | ||
| Gonadorelin | Which Factrel and Lutrepulse products are human products? US human Factrel and Lutrepulse applications are historical, and all listed strengths are discontinued. Current US Factrel is an FDA-labeled intramuscular cattle product. In Canada, Lutrepulse 0.8 mg is cancelled post-market and 3.2 mg is dormant. | ||
| GSK-2881078 | What is GSK-2881078, and has anything been approved? GSK-2881078 is a research compound, a selective androgen receptor modulator with no marketed product. An openFDA query on 9 October 2026 returned no GSK2881078 application, and no approval in any country is documented in the sources reviewed. | ||
| GUBamy | What is GUBamy, and is it approved? GUBamy, GUB014295 and ABBV-295 are one investigational long-acting amylin analogue, discovered by Gubra and licensed to AbbVie. FDA database searches on 10 October 2026 found no application or label, and company releases state it has not been approved by any regulator worldwide. |
| |
| GW-0742 | Is GW-0742 approved or allowed in tested sport? The cited regulatory and clinical records show no approved medicine or human clinical program. WADA's 2026 S4.4.1 section prohibits PPAR-delta agonists at all times using an including-but-not-limited-to list. GW-0742 is not named individually; the class placement follows its primary pharmacology. | ||
| hcg | Is the question about an ovulation trigger, a male endocrine condition, testosterone use, or weight loss? Those are four different evidence records. Female fertility and selected male hypogonadotropic hypogonadism are established label contexts. Use alongside testosterone is off-label and supported by small studies with surrogate or semen endpoints. Weight-loss claims are contradicted by controlled evidence and FDA labeling. | ||
| Hexarelin | What is hexarelin, and has FDA approved it? Hexarelin (examorelin) is a synthetic hexapeptide with no matching Drugs@FDA application and no ClinicalTrials.gov record in searches on 9 October 2026. Vendor material is normally the acetate salt, so a milligram of powder is not a milligram of peptide. | ||
| hgh | Is growth hormone allowed in tested sport or ordinary enhancement sales? The 2026 WADA list prohibits growth hormone, its analogs, and named long-acting products at all times in covered sport. US law also gives hGH a special distribution rule: knowingly distributing or possessing it with intent to distribute for a non-authorized use can trigger the penalty in 21 U.S.C. 333(e). | ||
| HGH Fragment 176-191 | Is HGH Fragment 176-191 FDA approved? The cited FDA records list no approved HGH Fragment 176-191 product or dosing label. WADA prohibits growth-hormone fragments for covered athletes. | ||
| Humanin | Is Humanin FDA approved? The cited FDA and clinical records include no approved native Humanin drug, prescribing label, or credible administered-human trial. | ||
| Hydrochlorothiazide | What is hydrochlorothiazide approved to do? Generic hydrochlorothiazide tablets are FDA-labeled for edema from heart failure, cirrhosis, corticosteroid and estrogen therapy and renal dysfunction, and for hypertension. The label does not mention androgens or anabolic steroids. | ||
| Hydromethylthionine | What is hydromethylthionine, and has any regulator approved it? Hydromethylthionine (HMTM, formerly LMTM, TRx0237) is a reduced form of the methylthioninium moiety of methylene blue, given in trials as a mesylate salt. It is not approved anywhere in the sources found: no FDA product turned up, and no MHRA decision was found as of 11 October 2026. | ||
| Ibutamoren | Is ibutamoren an FDA-approved drug or dietary supplement? No. FDA stated in September 2025 that ibutamoren is not an approved active ingredient and that its safety and efficacy have not been established. FDA also lists ibutamoren mesylate in Category 2 for both 503A and 503B compounding because of potential significant safety risks. | ||
| IGF-1 DES | What is des(1-3)IGF-1, and is it approved for anything? Des(1-3)IGF-I is a naturally occurring N-terminal truncation of IGF-I that lacks Gly-Pro-Glu and is a separate molecule from IGF-1 LR3. No approval for it appears in the records reviewed, and an antidoping laboratory states it was never approved for use in humans. | ||
| IGF-1 LR3 | Is IGF-1 LR3 FDA approved? The cited FDA and clinical records include no approved IGF-1 LR3 drug, prescribing label, or registered human trial. WADA prohibits IGF-1 analogues for covered athletes. | ||
| Ipamorelin | Is ipamorelin FDA approved? The cited FDA records list no approved ipamorelin drug. FDA lists compounding safety concerns, and WADA prohibits growth-hormone secretagogues for covered athletes. | ||
| Isotretinoin | What is isotretinoin approved to do? FDA approved isotretinoin as ACCUTANE in 1982 for severe recalcitrant nodular acne. The label reserves it for patients 12 and older whose acne did not respond to conventional therapy including systemic antibiotics. | ||
| ISRIB | What is ISRIB, and what is its regulatory status? ISRIB is a research compound, PubChem CID 1011240, that blocks the integrated stress response by binding eIF2B. It has no label and no registered study, and the clinical-stage drugs grouped with it, DNL343 and fosigotifator, are separate molecules. | ||
| ITPP | Is ITPP an approved medicine or allowed performance aid? The cited regulatory records list no approved indication. ClinicalTrials.gov currently labels NCT02528526 UNKNOWN and still shows an estimated 69 participants; the publication reports 28 treated people. WADA does not name ITPP, while M1.2 prohibits artificial enhancement of oxygen uptake, transport, or delivery. | ||
| J147 | What exactly is J147? J147 is a synthetic neurotrophic small-molecule drug candidate. FDA GSRS lists J147, while some public synonym databases attach a different CAS number. The cited FDA records list no Alzheimer's approval. | ||
| JBSNF-000088 | What is JBSNF-000088, and what is its regulatory status? JBSNF-000088 is 6-methoxynicotinamide, a small-molecule analog of nicotinamide that inhibits nicotinamide N-methyltransferase (NNMT). DailyMed returned no label and ClinicalTrials.gov no study. | ||
| KAI-4729 | What is KAI-4729, and is it approved anywhere? KAI-4729 (HRS-4729 at Hengrui) is a once-weekly injectable GLP-1, GIP and glucagon receptor triple agonist in clinical development for obesity, with Kailera holding rights outside Greater China. No approval or marketing application appears in any source reviewed, and PubChem has no record, so no formula, molecular weight or sequence is available. | ||
| Ketoconazole | What is ketoconazole approved to do? FDA-approved topical ketoconazole covers dandruff (1% over-the-counter shampoo) and tinea versicolor (2% shampoo), and neither label makes a hair-loss claim. Oral tablets are limited to serious systemic fungal infections and carry a boxed warning. |
| |
| Ketotifen | What is ketotifen approved to do? Every ketotifen application in Drugs@FDA is ophthalmic: eye drops first approved in 1999, the over-the-counter ALAWAY in 2006, and a drug-eluting contact lens in 2022. Oral ketotifen is nationally authorized in several EU countries. |
| |
| Kisspeptin-10 | Is kisspeptin-10 an FDA-approved treatment? The cited FDA records list no approved kisspeptin-10 product. FDA lists compounding safety concerns, and WADA prohibits kisspeptin and agonist analogues as testosterone-stimulating peptides in males. | ||
| KPV | Did the 2026 FDA review approve KPV? No. FDA staff recommended against 503A bulks-list inclusion, and the advisory process did not create drug approval. The cited FDA records list no approved KPV product or dosing label. | ||
| L-carnitine | What is levocarnitine injection actually approved to treat? The U.S. label covers acute or chronic secondary carnitine deficiency caused by inborn errors of metabolism and prevention or treatment of deficiency in people with end-stage renal disease on dialysis. It does not list obesity, weight loss, or athletic performance. | ||
| L-tetrahydropalmatine | What is L-tetrahydropalmatine, and is it approved? L-THP is a plant alkaloid that a 2012 review says has been approved and used in China as Rotundine. openFDA and DailyMed queries on 9 October 2026 returned no US application or label. | ||
| Larazotide | Is larazotide an FDA-approved or commercially established medicine? The cited FDA records list no approved larazotide product or prescribing label. The celiac program did not reach approval, and the completed Long COVID trial has not posted results. | ||
| Lemborexant | What is lemborexant approved to do? Lemborexant is a dual orexin OX1R/OX2R antagonist approved for adult insomnia in the United States and other named jurisdictions. | ||
| Letrozole | What is letrozole approved to do? FDA approved FEMARA (letrozole) on 25 July 1997. It is labeled only for postmenopausal women with breast cancer, and the label carries no indication in men. | ||
| Levothyroxine | What is levothyroxine approved to treat? Levothyroxine is synthetic T4. The US label covers replacement for primary, secondary, tertiary, congenital, or acquired hypothyroidism and adjunctive TSH suppression in selected differentiated thyroid cancer. Tissues convert T4 to active T3; liothyronine is a separate compound with different kinetics. | ||
| LGD-2226 | Is LGD-2226 approved or allowed in tested sport? The cited regulatory and clinical records show no approved medicine or active human program. WADA's 2026 S1.2 rule prohibits the SARM class with an open-ended list of examples. The primary papers identify LGD-2226 as a SARM. | ||
| LGD-3303 | Is LGD-3303 approved or permitted in tested sport? The cited regulatory and clinical records show no approved medicine or clinical development result. WADA's 2026 S1.2 section prohibits the SARM class at all times with an open-ended list of examples. The primary papers identify LGD-3303 as a SARM; the list does not name it individually. | ||
| Ligandrol | Is ligandrol approved or permitted in sport? The cited FDA records list no approved ligandrol product. FDA treats marketed SARM bodybuilding products as unapproved drugs, and WADA prohibits ligandrol for covered athletes. | ||
| Liothyronine | What is liothyronine approved to do? Liothyronine is synthetic T3, the more immediately active thyroid hormone. US Cytomel is approved for thyroid replacement, adjunctive TSH suppression in selected differentiated thyroid cancer, and selected diagnostic suppression. Obesity, weight loss, and bodybuilding are outside the indication and inside the boxed warning. | ||
| liraglutide | What is the difference between Saxenda and Victoza? Both products contain liraglutide, but Saxenda is the chronic weight-management product and Victoza is the type 2 diabetes product with its own cardiovascular-risk-reduction indication in labeled adults. Their labels, dose ceilings, age criteria, and trial outcomes must stay attached to the product. | ||
| Lithium orotate | What is lithium orotate, and how is it different from prescription lithium? Lithium orotate is a lithium salt sold as a supplement, while prescription lithium is lithium carbonate, FDA-labeled for bipolar I disorder in patients 7 years and older and not for brain aging. On 11 October 2026, Drugs@FDA and DailyMed searches found no lithium orotate drug or label. | ||
| Livagen | What is Livagen, and is it an approved drug? Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA) from the Khavinson group, made from an analysis of liver polypeptide preparations. openFDA Drugs@FDA and DailyMed return no product named Livagen and ClinicalTrials.gov returned no study, so no FDA record was found. Liver extracts such as Ventvil and Hepalin are different products. | ||
| LL-37 | What is LL-37, and has FDA approved it? LL-37 is the 37-residue C-terminal peptide of human cathelicidin (hCAP-18). Drugs@FDA queries for LL-37, cathelicidin and ropocamptide returned no matching application on 9 October 2026, so no LL-37 product is approved in the FDA record. | ||
| Low-dose naltrexone | What is low-dose naltrexone, and is it approved? LDN is naltrexone taken at a few milligrams a day, not a separate molecule. FDA approved naltrexone tablets in 1984, and the current label covers alcohol dependence and opioid blockade; no application covers fibromyalgia, autoimmune disease or mood, and none lists a single-ingredient product below 25 mg. | ||
| Magnesium glycinate | What is magnesium glycinate, and is it approved? Magnesium glycinate, also called magnesium bisglycinate or diglycinate, is the magnesium salt of two glycine molecules, about 14% magnesium by mass. No FDA-approved single-ingredient drug product exists, so there is no label, approved indication or labeled dose for it. | ||
| Maridebart cafraglutide | What is maridebart cafraglutide, and is it approved? Maridebart cafraglutide (MariTide) is Amgen's antibody-peptide conjugate: a GIP receptor antagonist antibody joined to two GLP-1 receptor agonist peptides. No US approval exists: openFDA and DailyMed searches on 10 October 2026 returned no application records and no labels. |
| |
| mazdutide | Where is mazdutide approved today? China approved mazdutide for chronic weight management in June 2025 and for glycemic control in adults with type 2 diabetes in September 2025. The Chinese weight label covers adults with BMI at least 28, or BMI at least 24 plus at least one weight-related comorbidity. The cited U.S. FDA records list no mazdutide approval. | ||
| Mecasermin | What does severe primary IGF-1 deficiency actually require? The current US label defines severe primary IGF-1 deficiency with all three of these findings: height standard-deviation score at or below -3.0, basal IGF-1 standard-deviation score at or below -3.0, and normal or elevated growth hormone. The indication is for growth failure in children age 2 or older who meet that definition, or who have a growth-hormone gene deletion and neutralizing antibodies to GH. | ||
| Melanotan I (afamelanotide) | What is FDA approved? Scenesse is FDA approved only as a 16 mg controlled-release implant to increase pain-free light exposure in adults with erythropoietic protoporphyria. Cosmetic tanning and other dosage forms are not that approved use. | ||
| Melanotan II | Is Melanotan II an approved tanning agent? No. FDA lists safety concerns for compounded Melanotan II, and TGA states that no Melanotan II product is registered or approved in Australia as a tanning agent. | ||
| Meldonium | What is meldonium, and where is it authorized? Meldonium (Mildronate) is authorized as a national medicine in Austria, Finland, Ireland and Norway for supplementary treatment of mild long-term heart failure in adults. No FDA-approved meldonium product turned up. | ||
| Menotropins | Is this about current female ART treatment or historical male gonadotropin evidence? The current US Menopur label is for developing multiple follicles and pregnancy in ovulatory women participating in an assisted-reproductive-technology cycle. It does not list a male indication. A 1985 male study addressed hypogonadotropic hypogonadism with staged hCG followed by historical hMG plus hCG, a different treatment question and product era. | ||
| Mesterolone | What is Proviron authorized to treat? Spain's current product information authorizes mesterolone for androgen replacement in adult men with androgen deficiency and for male infertility associated with male hypogonadism. The cited U.S. FDA records list no approval or labeled indication for idiopathic infertility, age-related optimization, physique use, or post-cycle treatment. | ||
| MET-233 | What is MET-233, and is it approved? MET-233 (written MET-233i by Metsera) is an investigational amylin analog developed by Metsera and now owned by Pfizer, which acquired Metsera on 13 November 2025. FDA database searches on 10 October 2026 found no application or label, and no structure or INN is public. |
| |
| Metformin | What does the D grade mean if metformin is an established medicine? The grade covers healthy-human longevity, not diabetes care. The current immediate-release label covers glycemic control in adults and children age ten and older with type 2 diabetes. It has no indication for lifespan extension, broad healthspan, dementia prevention, or improving exercise adaptation. | ||
| Methandienone | Is the old US approval still valid? The cited Par approvals were withdrawn in 1985 and the Bolar approvals in 1986. No current online product inherits those approvals. | ||
| Methasterone | What is methasterone, and what is its legal status? Methasterone (Superdrol) is a 17-alpha-alkylated oral anabolic steroid that DEA classified as a Schedule III controlled substance in 2012. There is no approved medical product and no label in the US record. | ||
| Methylcobalamin | What is methylcobalamin, and is it an approved drug? Methylcobalamin is a form of vitamin B12 with a methyl group on the cobalamin core. An openFDA query on 9 October 2026 found no FDA-approved methylcobalamin drug, while the same database lists approved cyanocobalamin products. | ||
| Methylene blue | Which methylene blue claim are you evaluating? The US approval covers acute IV rescue treatment for acquired methemoglobinemia. Oral cognition experiments, perioperative IV prevention, an oral colonoscopy dye, and retail nootropic products use different formulations, routes, populations, and outcomes. | ||
| Mibolerone | What is mibolerone, and who has approved it? Mibolerone is 7-alpha,17-alpha-dimethyl-19-nortestosterone, nandrolone with two added methyl groups. Its only approval in the US record is veterinary, for preventing estrus in adult female dogs. It has no human product and is a Schedule III controlled substance. | ||
| MID-35 | Is MID-35 approved or allowed in tested sport? The cited regulatory and clinical records show no approved medicine or human trial. WADA's 2026 S4.3 section prohibits agents that modify myostatin function, including myostatin inhibitors, at all times. MID-35 is not named individually, so the anti-doping statement rests on its intended mechanism rather than a molecule-specific listing. | ||
| Minoxidil | Which uses are actually approved? US topical minoxidil products have OTC labeling for specified pattern hair loss. Oral minoxidil is approved for severe refractory hypertension, not hair loss. | ||
| Mirabegron | What is mirabegron approved to do? FDA approved mirabegron as MYRBETRIQ in 2012 for overactive bladder in adults and later for neurogenic detrusor overactivity in children. There is no labeled use for obesity, fat loss or body composition. | ||
| Mirodenafil | What is mirodenafil approved to do? South Korea's MFDS approved Mvix (mirodenafil) tablets on 18 July 2007 as a prescription drug for erectile dysfunction. No US approval was found on 9 October 2026. | ||
| Modafinil | Is this treatment of a sleep disorder or an enhancement claim? US Provigil is approved to improve wakefulness in adults with excessive sleepiness tied to narcolepsy, obstructive sleep apnea, or shift-work disorder. The approval does not cover cognitive enhancement in rested healthy people. |
| |
| MOTS-c | Did FDA approve MOTS-c in 2026? FDA staff recommended against 503A bulks-list inclusion in the July 2026 review, and the cited FDA records list no approved MOTS-c drug or dosing label. WADA's 2026 Prohibited List, in effect since 1 January 2026, names MOTS-c under S4.4.1, activators of AMP-activated protein kinase, which are prohibited at all times. The 2027 list, which takes effect on 1 January 2027, keeps the same entry. | ||
| N-acetylcysteine | What is N-acetylcysteine approved to do? FDA first approved acetylcysteine as a drug in 1963. It is labeled as an acetaminophen overdose antidote and, as an inhaled solution, for thick mucus. FDA's 2022 guidance treats NAC as excluded from the supplement definition while it exercises enforcement discretion for products labeled as supplements. |
| |
| NAD+ | Is IV NAD+ an FDA-approved anti-aging treatment? The cited FDA records list no approved IV NAD+ anti-aging or wellness indication. FDA's Category 1 nomination status under 503A means the substance is still under evaluation, and the 2026 warning letter separately found NAD+ ineligible for that outsourcing facility's 503B exemptions. | ||
| Nandrolone | What does the current regulatory record show? US Deca-Durabolin approval was withdrawn in 2024. Australia retains a specific nandrolone decanoate registration. | ||
| Nebivolol | Is nebivolol an approved blood-pressure drug or an experimental nitric-oxide compound? US approval covers hypertension, and the label says controlled nebivolol trials have not shown cardiovascular-risk reduction. The UK SmPC also covers stable mild or moderate heart failure in patients 70 or older, based on evidence that includes SENIORS. | ||
| Nicotinamide riboside | What is nicotinamide riboside, and is it approved? Nicotinamide riboside (NR) is a small molecule sold as NR chloride, a food and supplement ingredient. FDA has no questions about a notifier's GRAS conclusion for conventional foods, EFSA found NR chloride safe at up to 300 mg/day in healthy adults, and no FDA-approved NR drug or label was found on 10 October 2026. | ||
| NMN | What did FDA change, and what did it not approve? FDA changed its prior interpretation that NMN was excluded from the dietary-supplement definition solely because of drug-investigation timing. That decision does not approve NMN as an anti-aging drug, verify a product, establish efficacy or settle every ingredient-status question. NDIN 1444 is a notification record, not a drug label. | ||
| Nooglutyl (nooglutil) | What is nooglutyl, and what is its regulatory status? Nooglutyl, also written nooglutil and ONK-10, is N-(5-hydroxynicotinoyl)-L-glutamic acid, PubChem CID 147523, a research compound from Russian pharmacology. It has no FDA label and no registered study, a calcium salt studied in 2019 is a separate form, and its status in Russia is not established here. | ||
| nortadalafil | Is nortadalafil generic Cialis? Generic Cialis contains tadalafil. Nortadalafil is a different chemical and does not share that approval. | ||
| NSI-189 phosphate | What is NSI-189 phosphate, and is it approved? NSI-189 phosphate is an investigational compound with no FDA approval record. openFDA queries for NSI-189 and for amdiglurax returned no application on 9 October 2026. | ||
| orforglipron | What exactly did FDA approve? FDA approved Foundayo, orforglipron tablets, on April 1, 2026 as an adjunct to a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or adults with overweight plus at least one weight-related comorbidity. | ||
| Orlistat | What is orlistat approved to do? FDA approved orlistat as prescription XENICAL in 1999 for obesity management and as over-the-counter alli in 2007 as a weight loss aid. Both products contain the same molecule at different strengths. | ||
| Osavampator | What is osavampator, and is it approved? Osavampator is the INN for TAK-653, also coded NBI-1065845, an investigational AMPA receptor potentiator with no FDA approval record. An openFDA query for osavampator returned no application on 9 October 2026. | ||
| Ovagen | What is Ovagen, and is it an approved drug? The Khavinson group's tables tie the name Ovagen to the tripeptide Glu-Asp-Leu (EDL), a link that PubChem does not make. openFDA Drugs@FDA returned no match for the name and ClinicalTrials.gov returned no study, so no FDA record of the peptide was found. Two other products share the name and are not the peptide. | ||
| Oveporexton | What is oveporexton, and has FDA approved it? FDA issued an approval letter for ORZEYFUL (oveporexton) dated 5 August 2026 for adults with narcolepsy type 1. The formal approval date and marketing wait on a DEA scheduling notice that a Federal Register search on 10 October 2026 did not find. | ||
| Oxandrolone | What is Anavar, and is it still FDA-approved? Anavar is a name for oxandrolone, an oral anabolic-androgenic steroid. Its US approvals were withdrawn in 2023. | ||
| Oxymetholone | Is Anadrol-50 currently marketed in the US? Drugs@FDA lists the Anadrol-50 oral product as Discontinued. Its application and historical label remain in Drugs@FDA. | ||
| oxytocin | What is Pitocin approved for? The Pitocin label covers the obstetric uses listed below. It excludes elective labor induction without a medical indication and does not approve social, psychiatric or sexual uses. | ||
| P021 | What is P021, and is it approved for anything? P021 is a small adamantane-containing peptide mimetic of 578.7 Da, described in the literature in more than one way. No approval for any use appears in the records reviewed, and ClinicalTrials.gov queries on 9 October 2026 returned no studies. | ||
| Pancragen | What is Pancragen, and is it an approved drug? Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW) from the Khavinson group. PubChem has no record under the name, and its free-acid record is CID 68452877. On 10 October 2026, FDA, DailyMed and ClinicalTrials.gov searches returned nothing under the name, so no approval was found. | ||
| PDRN (polydeoxyribonucleotide) | What is PDRN, and is it an approved drug? PDRN (polydeoxyribonucleotide) is a mixture of DNA fragments purified from salmon sperm, not a single molecule, and products differ. No FDA approval was found on 11 October 2026. An Italian product, PLACENTEX, is described as a tissue-repair medicine for wounds and ulcers, but only in a 2017 secondary copy of its package leaflet. | ||
| PE-22-28 | Is PE-22-28 approved? No FDA-approved PE-22-28 drug, prescribing label, or registered human trial was identified. | ||
| PEG-MGF | What are MGF and PEG-MGF, and are they approved for anything? The name MGF covers a gene splice variant and a synthetic 24-residue peptide, and PEG-MGF is the pegylated form of that peptide that is sold. No approval for MGF or PEG-MGF appears in the records reviewed, and a PubMed search for the exact phrase PEG-MGF returned one record, a review. | ||
| Pemvidutide | What is pemvidutide, and is it approved anywhere? Pemvidutide (code ALT-801) is a once-weekly injectable GLP-1 and glucagon dual receptor agonist from Altimmune. It is not approved: no FDA application record or label turned up on 10 October 2026, and no approval appears in any source reviewed. No formula or molecular weight is established. | ||
| Petrelintide | What is petrelintide, and is it approved? Petrelintide is an investigational long-acting amylin analogue with no FDA approval record. Searches of FDA's Drugs@FDA and DailyMed on 10 October 2026 found no application or label under that name. The EMA was not searched. |
| |
| Phenibut | What is phenibut, and what is its regulatory status? Phenibut (beta-phenyl-GABA), related to baclofen, is a Russian prescription medicine. No FDA-approved phenibut drug turned up, FDA says supplements containing it are misbranded, and a 2024 German review says it is illegal in Germany. |
| |
| Phentermine | What is phentermine approved to do? The generic phentermine label (initial U.S. approval 1959) indicates it as a short-term adjunct to a weight-reduction regimen in exogenous obesity, for a BMI of 30 or more, or 27 or more with risk factors. Phentermine is a Schedule IV drug. |
| |
| phenylpiracetam | Where is phenylpiracetam recognized or unapproved? A Russian Ministry-format label covers licensed oral tablets and describes named uses, PK and safety. FDA identifies phenylpiracetam in a US unapproved-drug distribution case. Russian recognition does not create US approval or verify the identity of an online product. | ||
| Picamilon | What is picamilon, and what is its regulatory status? Picamilon is nicotinoyl-GABA, registered in Russia as a nootropic tablet. No FDA-approved picamilon drug turned up, and FDA says supplements containing it are misbranded because it is not a dietary ingredient. | ||
| Pinealon | Is Pinealon approved? No FDA-approved Pinealon drug, US prescribing label, or registered exact-intervention trial was identified. | ||
| PNC-27 | What is PNC-27, and is it approved for anything? PNC-27 is a laboratory peptide made of a p53 fragment joined to a penetratin cell-penetrating domain. There is no approved or validated human use: no registered clinical trial and no FDA application appear in the records reviewed, and no human has been given it. | ||
| PP405 | What is PP405, and has anyone approved it? PP405 is an investigational topical gel for androgenetic alopecia from Pelage Pharmaceuticals, with the same structure as JXL069, a compound described in cells and mice. No approval was found: openFDA returned no record and DailyMed no label for PP405, suvomipic or JXL069 on 10 October 2026. | ||
| PPAP (phenylpropylaminopentane) | What is PPAP, and what is its regulatory status? PPAP (phenylpropylaminopentane) is a deprenyl-derived research compound. The research used the (-)-enantiomer, so a racemic or unspecified vendor product is not the studied material, and no label, application or registered study exists. | ||
| PQQ | What do EU, Chinese and US food records mean? EU novel-food authorization, Chinese new-food-raw-material actions and FDA GRAS Notice 694 apply to specified PQQ disodium preparations and food uses. They do not approve PQQ for memory, disease treatment or anti-aging. The EU excludes pregnant and lactating people; China also excludes infants. | ||
| Pramlintide | What is pramlintide approved to do? FDA labels SYMLIN as an adjunct for people with type 1 or type 2 diabetes who use mealtime insulin and have not reached glucose goals despite optimal insulin therapy. Pramlintide is a synthetic analog of human amylin, and the label does not include weight loss or obesity. | ||
| PRL-8-53 | What is PRL-8-53, and what is its regulatory status? PRL-8-53 is methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate, studied as the hydrochloride. No US approval, label, scheduling or enforcement record names it, and the WADA 2026 list does not name it. | ||
| Propranolol | What is propranolol approved to do? Propranolol hydrochloride tablets are FDA-labeled for eight conditions, including hypertension, angina, atrial fibrillation rate control, lower cardiovascular mortality after myocardial infarction, migraine prophylaxis and essential tremor. Anxiety, insomnia and stimulant effects are not labeled indications. | ||
| Prostamax | What is Prostamax, and is it an approved drug? Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson group, which the group's 2022 table spells Prostomax. openFDA Drugs@FDA and DailyMed return no product named Prostamax and ClinicalTrials.gov returned no study, so no FDA record was found. | ||
| PT-141 | Who is Vyleesi FDA approved for? The current label covers premenopausal women with acquired, generalized HSDD. Acquired means low desire developed after a period without the problem. Generalized means it occurs across types of stimulation, situations, and partners. The low desire must cause marked distress or interpersonal difficulty and must not be due to a coexisting medical or psychiatric condition, relationship problems, or a medication or drug. | ||
| Pyrilutamide | What is pyrilutamide, and has anyone approved it? Pyrilutamide (KX-826) is an investigational topical androgen receptor antagonist for androgenetic alopecia, sponsored by Suzhou Kintor Pharmaceutical. No drug approval was found: openFDA returned no record and DailyMed no label on 10 October 2026. | ||
| RAD-140 | Is RAD-140 approved, and is it allowed in tested sport? RAD-140 is investigational, and no FDA-approved finished product appears in the cited US regulatory records. FDA's December 2025 Atomix warning letter identifies a marketed RAD-140/Testolone product as an unapproved new drug. WADA explicitly names RAD140 among SARMs prohibited at all times in 2026. | ||
| Raloxifene | What is raloxifene approved to do? FDA approved EVISTA (raloxifene) on 9 December 1997 for osteoporosis in postmenopausal women and for reducing invasive breast cancer risk in postmenopausal women with osteoporosis or at high risk. The label states there is no indication for use in men and that use in men is not recommended. | ||
| Rapamycin | What does the D grade mean if sirolimus is FDA approved? The grade concerns healthy-human longevity. It does not dispute the product-specific approvals for Rapamune, Hyftor, or Fyarro. None of the current labels has a healthy-aging, lifespan-extension, broad-healthspan, or cognitive-enhancement indication. | ||
| retatrutide | Is retatrutide FDA approved, and what product was actually studied? No. Lilly states that retatrutide is investigational and has not been approved by any regulator. Trial results apply to Lilly's controlled study drug, not products sold online under the same name. | ||
| Retinalamin | What is Retinalamin, and where is it registered? Retinalamin is a mixture of water-soluble polypeptide fractions from cattle retina, given by intramuscular or parabulbar injection. It is registered in Russia under Gerofarm LLC, and no US application, label or registered trial was found. | ||
| RGPU-95 | What is RGPU-95, and what is its regulatory status? RGPU-95 is a research code sold as para-chlorophenylpiracetam. PubChem has no record under the code, and the link from the code to that structure rests on secondary pages, not a primary source. No US approval, label or scheduling record names it. | ||
| Ribupatide | What is ribupatide, and is it approved anywhere? Ribupatide is the WHO Proposed INN for a synthetic peptide described as a dual GIP and GLP-1 receptor agonist, one molecule with HRS9531 and KAI-9531. No FDA approval exists, and Kailera's filings describe a pending NDA in China submitted by Hengrui, with no decision found. | ||
| Rosuvastatin | What is rosuvastatin approved to do? CRESTOR is labeled to reduce the risk of major cardiovascular events in adults at increased risk, to lower LDL-C in hypercholesterolemia, to slow progression of atherosclerosis, and for familial hypercholesterolemia and other lipid disorders. The label lists initial U.S. approval in 2003. | ||
| Roxadustat | What is roxadustat approved to do? Roxadustat is approved for anemia of chronic kidney disease in the EU (Evrenzo, 18 August 2021), China, Japan, Chile and South Korea. No FDA-approved roxadustat product was located on 9 October 2026, and the sponsor reported an FDA complete response letter in August 2021. |
| |
| RU58841 | Is RU58841 FDA approved? No US approved-drug record appears for RU58841 or PSK3841 in Drugs@FDA or openFDA. This conclusion is limited to US approval records. | ||
| S-23 | What is S-23, and what is its regulatory status? S-23 is an arylpropionamide selective androgen receptor modulator (SARM) in the same chemical family as andarine. It has no FDA match or label, and the WADA 2026 list names it explicitly as prohibited at all times. | ||
| Safiglipron | What is safiglipron, and is it approved anywhere? Safiglipron (INN) is the name for the oral small-molecule GLP-1 receptor agonist known as HRS-7535 at Hengrui and KAI-7535 at Kailera. It is not approved anywhere in the sources reviewed. A brokerage repost dated 2 September 2026 reports an NMPA acceptance notice for the type 2 diabetes application, and no US application or label was found. | ||
| SANA (MVD1) | Has SANA been approved or followed by a larger efficacy trial? The cited records include the first-in-human study but no exact-name FDA approval or posted larger efficacy result under SANA, MVD1, or ACTRN12622001519741. | ||
| SAR441255 | What is SAR441255, and has anyone approved it? SAR441255 is a synthetic peptide agonist of the GLP-1, glucagon and GIP receptors, based on exendin-4 and developed by Sanofi. It has never been approved. A Drugs@FDA query on 9 October 2026 returned no matching application, and PubChem has no record, so no formula, molecular weight or CAS number can be confirmed from an official database. | ||
| Selank | Is Selank FDA approved, and are its nasal drops registered in Russia? No FDA-approved Selank drug appears in the cited US approval records. A Russian drug-reference reproduction lists 0.15% nasal drops under replacement registration ЛП-№(010951)-(РГ-RU), dated July 15, 2025, with an indefinite term. | ||
| Seltorexant | Is seltorexant the same as lemborexant? No. Seltorexant selectively blocks OX2R and remains investigational. Lemborexant blocks OX1R and OX2R and has separate approvals. | ||
| semaglutide | What is the difference between Ozempic, Wegovy and Rybelsus? They contain the same active ingredient, semaglutide. Their forms, strengths and approved uses differ. Some brand names now cover both injections and tablets. | ||
| Semax | Is Semax FDA approved or cleared for compounding? No Semax substance is a component of an FDA-approved drug. In July 2026, FDA staff concluded that the evidence weighed against placing Semax free base and Semax acetate on the 503A bulks list, citing poor characterization, intranasal-device questions, limited safety information, immunogenicity concern, and insufficient effectiveness evidence for the nominated uses. | ||
| Sermorelin | Is sermorelin currently FDA approved? No current FDA-approved sermorelin product was identified. Historic Geref products were withdrawn from sale; FDA later determined that the withdrawal was not for safety or effectiveness, which permits certain abbreviated applications but provides no current approval or adult-wellness indication. | ||
| Setmelanotide | What is setmelanotide approved to do? FDA labels IMCIVREE to reduce excess body weight and maintain the reduction long term in patients 4 years and older with acquired hypothalamic obesity, and in patients 2 years and older with Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. The label excludes general (polygenic) obesity, where it would not be expected to be effective. | ||
| Sildenafil | What is sildenafil approved to do? FDA approved sildenafil for erectile dysfunction as VIAGRA in 1998 and for pulmonary arterial hypertension as REVATIO in 2005. | ||
| Sipagladenant | What is sipagladenant, and is it approved? Sipagladenant is the INN for KW-6356, an investigational adenosine A2A receptor antagonist with no FDA approval record. openFDA queries for KW-6356 and for sipagladenant returned no application on 9 October 2026. | ||
| Sitagliptin | What is sitagliptin approved to do? FDA approved JANUVIA (sitagliptin) on 16 October 2006 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Use alongside injected peptides is not a labeled use. | ||
| SNAP-8 | Is SNAP-8 an approved wrinkle drug? No FDA-approved SNAP-8 drug or exact registered therapeutic intervention appears in the cited US approval and trial records. Sale as a cosmetic ingredient does not establish drug approval or a Botox-equivalent effect. | ||
| Sobetirome | What is sobetirome, and is it approved? Sobetirome (GC-1, QRX-431) is a thyroid hormone receptor beta-selective research chemical with no FDA application located on 9 October 2026. GC-1 is also the name of a mouse cell line, which corrupts literature searches. | ||
| Spermidine | What is spermidine, and what is its regulatory status? Spermidine is a natural polyamine sold as a supplement, and the products in trials are not one thing: wheat germ and rice germ extracts giving 0.9 to 3.3 mg per day and a purified trihydrochloride at 40 mg per day. On 11 October 2026, Drugs@FDA and DailyMed searches found no spermidine drug or label. | ||
| Spironolactone | What is spironolactone approved to do? FDA approved ALDACTONE (spironolactone) on 21 January 1960. It is labeled for heart failure, hypertension, edema and primary hyperaldosteronism, and it has no label indication for acne, hirsutism or hair loss. | ||
| SR-9009 | What is SR-9009, and what is its regulatory status? SR-9009 is a synthetic REV-ERB agonist from mouse and cell research, paired in print with the trade name Stenabolic. DailyMed returned no label and ClinicalTrials.gov no study, and the name alone does not settle what is in a given vial. | ||
| SR-9011 | Is SR-9011 approved or permitted in tested sport? No approved medicine or human clinical program appears in the cited records. WADA's 2026 S4.4.1 section explicitly names SR9011 among REV-ERB-alpha agonists prohibited at all times. | ||
| SS-31 (elamipretide) | Who is Forzinity FDA approved for? FDA granted accelerated approval to Forzinity on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. It is administered once daily by subcutaneous injection. | ||
| Stanozolol | Is a former US brand the same as a current approved medicine? No. FDA withdrew the Winstrol tablet approval in 2010. The separate Winsteroid approval was withdrawn in 2024 for failure to submit required reports. | ||
| Sunifiram (DM-235) | What is sunifiram, and what is its regulatory status? Sunifiram (DM-235) is an acylpiperazine research compound, PubChem CID 4223812, and a different molecule from unifiram (DM-232). It has no FDA label, no application and no registered study. | ||
| survodutide | Is survodutide approved? Survodutide remains investigational in the United States. FDA designations and phase 3 enrollment can speed or structure development, but they are not marketing approval. | ||
| tadalafil | Why does the same molecule have three different clinical stories? Cialis is labeled for erectile dysfunction, benign prostatic hyperplasia symptoms, and their combination. Adcirca is labeled for pulmonary arterial hypertension. They contain tadalafil, but use different clinical endpoints and product instructions. | ||
| Tamoxifen | What is tamoxifen approved to do? Tamoxifen has been FDA-approved since 1977 and is labeled for breast cancer in women and men. Use for gynecomastia prevention or recovery after steroid cycles is not a labeled use. |
| |
| Taurine | What is taurine, and what is its US status? Taurine is an endogenous amino sulfonic acid, the same single molecule in every study on this page. In FDA records it appears only as one ingredient in four intravenous amino acid nutrition products, which are not a taurine drug and are not approved for aging or longevity. | ||
| TB-500 | Is TB-500 FDA approved or allowed in tested sport? No FDA-approved TB-500 drug appears in the cited US records. FDA staff recommended against 503A bulks-list inclusion in July 2026, and WADA prohibits thymosin beta-4 derivatives including TB-500. | ||
| TB-500 Fragment | Is TB-500 Fragment approved? No FDA-approved LKKTETQ product or dosing label appears in the cited US records. FDA lists safety concerns for thymosin beta-4 fragment, and WADA prohibits thymosin beta-4 derivatives for covered athletes. | ||
| Telmisartan | Is telmisartan just a blood-pressure drug? Telmisartan is approved for hypertension. The US label also covers reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk adults aged 55 or older who cannot take ACE inhibitors. The EU record uses different prevention wording, so the jurisdiction and patient definition matter. | ||
| Teriparatide | What is teriparatide approved to do? FDA approved FORTEO (teriparatide) on 26 November 2002 for osteoporosis at high fracture risk in postmenopausal women, in men with primary or hypogonadal osteoporosis, and in glucocorticoid-associated osteoporosis. FORTEO is not approved in pediatric patients. | ||
| tesamorelin | What problem is tesamorelin FDA approved to treat? The current Egrifta WR label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. The label explicitly says it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. | ||
| Tesofensine | Is tesofensine approved in Mexico or the United States? The cited US records list no FDA-approved tesofensine drug. The cited COFEPRIS record covers an application and resubmission, not final authorization in Mexico. | ||
| Testagen | What is Testagen, and is it an approved drug? Testagen is a trade name that a 2011 abstract and the Khavinson group's 2022 table tie to the tetrapeptide Lys-Glu-Asp-Gly (KEDG); PubChem does not make that link. DailyMed returns no label named Testagen, and ClinicalTrials.gov returned no study for the tetrapeptide, so no FDA record of the peptide was found. A registered topical testosterone product shares the name and is not the peptide. | ||
| testosterone | What does prescription approval cover? US testosterone products are approved for specified causes of testosterone deficiency. Their labels retain a limitation that safety and efficacy for age-related hypogonadism have not been established. | ||
| Thozalinone | What is thozalinone, and what is its regulatory status? Thozalinone (CL-39808) is PubChem CID 12602, the N,N-dimethyl analog of pemoline. No US label, scheduling or enforcement record names it, and the WADA 2026 list names pemoline but not thozalinone. A product named Stimsen existed, but its status in any country is not shown. | ||
| Thymalin | Is Thymalin an approved or registered drug? The cited US and EU records contain no Thymalin approval, and public trial registries contain no exact-name intervention study. A developer-authored account reports a 1982 Soviet registration; that secondary account does not imply US or EU approval. Older unregistered human reports remain separate evidence. | ||
| Thymogen (oglufanide) | What is Thymogen, and where is it approved? Thymogen is the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp, oglufanide), first found in the calf thymus extract Thymalin. A commercial Russian drug reference lists three Thymogen products, and no FDA approval or label was found on 10 October 2026. | ||
| thymosin α-1 | Where and for what is thymalfasin currently authorized? China's national pharmaceutical data center lists Zadaxin thymalfasin for injection, 1.6 mg, under registration 国药准字HJ20171177 through May 5, 2027. The Chinese instruction names compensated chronic hepatitis B and vaccine-response enhancement in immunocompromised people. Sepsis and general wellness are not named indications. No exact-name FDA approval appears in the cited US records. | ||
| Thymulin | What is thymulin, and is it an approved drug? Thymulin is a nine-residue peptide hormone made by thymic epithelial cells, and its activity depends on zinc. On 10 October 2026, openFDA Drugs@FDA queries for thymulin and for nonathymulin returned no match, and the one US label found is an unapproved homeopathic pellet. | ||
| Tianeptine | What is tianeptine, and where is it approved? Tianeptine is a prescription antidepressant authorized in France since 6 February 1987. FDA states it is not approved for any medical use in the US and does not meet the statutory definition of a dietary ingredient, yet it is sold as a supplement and a nootropic. |
| |
| tirzepatide | What is tirzepatide FDA approved to treat? In the US, Zepbound is approved for long-term weight management in adults with obesity, or overweight with a weight-related condition. It also treats moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro treats type 2 diabetes in adults and children age 10 years and older, and is approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them. | ||
| TND1128 | What is TND1128, and what is its regulatory status? TND1128 is a 5-deazaflavin derivative described in three papers from 2021 to 2024. PubChem has no record under the code, and the match to CID 322148 rests on the 2021 paper's chemical name. No label or registered study exists. | ||
| Topilutamide (fluridil) | What is topilutamide (fluridil), and has anyone approved it? Topilutamide and fluridil are one compound, a topical anti-androgen. No drug approval was found on 10 October 2026, a 2006 paper calls the studied product, Eucapil, a cosmetic, and a 2008 company press release said it was sold outside the US. | ||
| Tranylcypromine | What is tranylcypromine approved to do? FDA approved PARNATE in 1961. The label is for major depressive disorder in adults who have not responded adequately to other antidepressants, and it is not indicated for initial treatment. | ||
| Trazodone | What is trazodone approved to do? FDA first approved trazodone as DESYREL in 1981 for major depressive disorder in adults. The tablet label has no insomnia indication, so sleep use is off-label. | ||
| Trenbolone | What is trenbolone, and what is it approved for? Trenbolone is an anabolic-androgenic steroid. The cited current US authorization is for acetate implants in cattle, not a human medicine. | ||
| Trestolone | Is trestolone approved or allowed in tested sport? No FDA-approved trestolone product appears in the cited US records. One US MENT gel study is registered as completed without posted results, which does not create an approval. WADA's 2026 list explicitly names trestolone and MENT as anabolic agents prohibited at all times. | ||
| Trevogrumab | What is trevogrumab, and is it approved? Trevogrumab (REGN1033) is an investigational Regeneron antibody that blocks myostatin. No regulator has approved it, and the 2026 US approval of garetosmab, the second antibody in one COURAGE arm, is for a rare bone disease only. | ||
| triptorelin | How do Trelstar, Triptodur and Decapeptyl differ? Trelstar and Triptodur are US pamoate depots with different approved uses. UK Decapeptyl products use the acetate salt and have their own release schedules and indications. The post-cycle case report does not identify its formulation or route. | ||
| Tropisetron | Where is tropisetron approved, and for what? Tropisetron is a registered prescription medicine in Australia, as intravenous ampoules for nausea and vomiting from cytotoxic therapy and after surgery. No FDA-approved tropisetron product was located, and the originator NAVOBAN licences in Ireland were withdrawn in 2000. | ||
| TUDCA (tauroursodeoxycholic acid) | What is TUDCA, and what did FDA approve? TUDCA (taurursodiol) is the taurine conjugate of ursodeoxycholic acid. FDA approved RELYVRIO, a fixed combination of sodium phenylbutyrate and taurursodiol for ALS, on 29 September 2022 and withdrew approval as of 29 August 2025. Taurursodiol has never been approved in the US as a single ingredient. | ||
| Turinabol | What is Turinabol, and what is its legal status? Turinabol is 4-chlorodehydromethyltestosterone, metandienone (Dianabol) with a chlorine at position 4. It is a Schedule III controlled substance in the United States, has no FDA label, and WADA prohibits it at all times. | ||
| UBT251 | What is UBT251, and is it approved? UBT251 is a long-acting triple agonist of the GLP-1, GIP and glucagon receptors from The United Laboratories, licensed to Novo Nordisk outside China, Hong Kong, Macau and Taiwan. No marketing approval or US label turned up on 10 October 2026. | ||
| Unifiram (DM-232) | What is unifiram, and what is its regulatory status? Unifiram (DM-232) is a bicyclic lactam with a sulfonamide, PubChem CID 9861054, and a different molecule from sunifiram (DM-235). It has a stereocenter, so a vendor product may be a racemate, and it has no FDA label, no application and no registered study. | ||
| Urolithin A | What is urolithin A, and what is its US status? Urolithin A is a single defined molecule that gut bacteria make from compounds in pomegranate, nuts and certain berries, and the ingredient in FDA's letter is made synthetically. FDA sent a no-questions letter in 2018 on a food-ingredient notice from Amazentis, which is not a drug approval and not an efficacy finding. | ||
| Vesugen | Is synthetic Vesugen an approved medicine? The cited public records contain no US or EU approval or Russian or Chinese medicine authorization for synthetic KED/Vesugen. | ||
| Vilon | Is Vilon approved? The cited US records contain no FDA-approved Vilon drug or registered intervention trial, and the cited sources include no current official Russian product label. | ||
| VIP | What is the regulatory answer for each product? No FDA-approved aviptadil or VIP drug appears in the cited US records. National authorization evidence exists for the aviptadil-plus-phentolamine intracavernosal combination used for erectile dysfunction; it does not authorize VIP alone, inhaled aviptadil, or an intranasal product. | ||
| VK2735 | What is VK2735, and is it approved anywhere? VK2735 is Viking Therapeutics' investigational dual agonist of the GLP-1 and GIP receptors, in subcutaneous and oral tablet forms. No approval in any jurisdiction was found: openFDA and DailyMed searches on 10 October 2026 returned no application record and no label. | ||
| YK-11 | Is YK-11 approved, legal, or permitted in sport? FDA identifies marketed YK-11 products as unapproved new drugs, and WADA prohibits YK-11 for covered athletes. These sources cover FDA enforcement and sports rules; they do not establish the legality of possession in a particular jurisdiction. | ||
| Yohimbine | What is yohimbine, and is it approved? Yohimbine is a defined molecule found in yohimbe bark, sold as the free base or hydrochloride salt. No FDA application record was found, and federal regulation treats any OTC product promoted as an aphrodisiac as a new drug that needs an approved application. | ||
| Zopiclone | Where is zopiclone approved, and for what? Zopiclone is authorized for short-term insomnia in the UK and has been available in the EU since the mid-1980s, and it is marketed in Canada. No FDA-approved zopiclone product was located; the US sells its S-enantiomer, eszopiclone, as LUNESTA. |
no sourced status section yet: 1,3-DMAA, 5-amino-1mq, Adrafinil, Albuterol, aminotadalafil, BAM15, Boldenone, bpc-157 + kpv blend, bpc+tb blend, Bromantane, chloropropanoylpretadalafil, coluracetam, fasoracetam, fladrafinil, flmodafinil, ghk-cu + bpc blend, glow, insulin, klow, L-oxiracetam, Methenolone, MK-777, nefiracetam, Noopept (omberacetam; GVS-111), oxiracetam, piracetam, pramiracetam, Pregnenolone, sermorelin + GHRP-2, SLU-PP-332, SLU-PP-915, tesa+ipa blend, tesamorelin + CJC-1295 + ipamorelin.
compounding
what section 503A allows
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist or physician may compound a drug only from bulk drug substances that meet an applicable USP or NF monograph; or, where no monograph exists, are components of an FDA-approved drug; or, where neither applies, appear on a list FDA develops by regulation, the 503A bulks list. Section 503A sets the conditions under which a compounded drug is exempt from three sections of the act, among them section 505, which concerns the approval of drugs under new drug applications. FDA adds substances to the bulks list by regulation: its February 2019 final rule placed six substances on the list, and it addresses other nominated substances through notice-and-comment rulemaking.
sources:21 U.S.C. 353a, Pharmacy compounding, United States Code (2024 edition); FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026); FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (introduction) (for the meeting of July 23-24, 2026)
interim policy
FDA's 503A categories
While it evaluates nominations, FDA keeps an interim policy that sorts nominated bulk drug substances into three categories. FDA says it does not intend to take action against a compounder using a category 1 substance when the conditions in its guidance are met, and that it would consider action under its general enforcement policies for category 2 and category 3 substances. Its guidance states that FDA does not intend to place substances nominated on or after January 7, 2025, into these categories.
sources:FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026)
The names below are FDA's own, from its category list updated May 14, 2026 and its category 2 safety page current as of April 22, 2026, for the compounds this site covers. A name links to a compound's page only where FDA's substance and the compound are the same without doubt.
sources:FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026)
Category 1: Bulk Drug Substances Under Evaluation
FDA's definition: “These substances may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list.”
- Coenzyme Q10
- Enclomiphene Citrate
- GHK-Cu (except for injectable routes of administration)
- Glutathione
- Methylcobalamin
- Nicotinamide Adenine Dinucleotide (NAD)
- Pregnenolone
- Vasoactive Intestinal Peptide
sources:FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026)
Category 2: Bulk Drug Substances that Raise Significant Safety Concerns
FDA's definition: “These substances were nominated with sufficient supporting information to permit FDA to evaluate them, and they may be eligible for inclusion on the 503A bulks list. However, FDA has identified significant safety risks relating to the use of these substances in compounding pending further evaluation and, therefore, does not intend to adopt the policy described for the substances in category 1.”
sources:FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026)
Category 3: Bulk Drug Substances Nominated Without Adequate Support
FDA's definition: “These substances may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them.”
- Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate (not linked: FDA's name does not say whether this salt is of NAD+ or of its reduced form, NADH)
- Cibinetide (ARA-290)
- GHRP-2
- GHRP-6
- Magnesium bisglycinate
- Magnesium bisglycinate dehydrate
- Magnesium glycinate
- Magnesium glycinate 15%
- Mechano growth factor (MGF) (not linked: this site's page covers the pegylated form, PEG-MGF, a different molecule)
- Piracetam dihydrogen citrate (not linked: a citrate form the piracetam page does not describe)
- Thylene blue (not linked: FDA's spelling; it may mean methylene blue, which the name does not settle)
- Thymulin acetate
sources:FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026)
Bulk drug substances nominated but withdrawn
FDA's note: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.”
- AOD-9604
- BPC-157
- Cathelicidin LL-37
- CJC-1295
- Dihexa acetate
- Emideltide (DSIP)
- Epitalon
- GHK-Cu (for injectable routes of administration)
- Ipamorelin acetate
- KPV
- Mechano growth factor pegylated (PEG-MGF)
- Melanotan II
- MOTs-C
- Selank acetate (TP-7)
- Semax (heptapeptide)
- Thymosin-alpha 1 (Ta1)
- Thymosin beta-4, fragment (LKKTETQ), also known as TB-500 (not linked: FDA's name fits both this site's tb-500 page (the market name) and its tb-500-frag page (the LKKTETQ fragment))
sources:FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026)
advisory committee
the July 23-24, 2026 committee meeting
The agenda for the July 23 and 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee covered seven groups of bulk drug substances being considered for the 503A bulks list: BPC-157, KPV, TB-500 and MOTS-c on July 23, and emideltide (also called DSIP), epitalon and semax on July 24, each as a free base and as an acetate. In its briefing document, FDA proposed that none of the 14 substances be included on the 503A bulks list. FDA announced the meeting in the Federal Register on April 16, 2026, and opened docket FDA-2025-N-6895 for comments.
sources:FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026); FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (introduction) (for the meeting of July 23-24, 2026); Federal Register, 91 FR 20465, Pharmacy Compounding Advisory Committee; Notice of Meeting (document 2026-07361) (published April 16, 2026)
FDA's meeting page says advisory committees make non-binding recommendations to FDA, which generally follows them but is not legally bound to do so. The briefing document adds that FDA does not intend to issue a final determination until the committee's input has been considered and all reviews have been finalized, and section 503A adds a substance to the bulks list only through regulations. News reports say the committee voted to recommend six of the seven, BPC-157, KPV, TB-500 and MOTS-c on July 23 and epitalon and semax on July 24, and voted against emideltide; FDA's meeting page carries no vote record. As of October 24, 2026, FDA has not posted minutes of the meeting on its meeting page, which was last updated August 6, 2026 and lists the briefing documents, FDA's presentations, the questions, the agenda, the roster and webcast information.
sources:FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026); FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (introduction) (for the meeting of July 23-24, 2026); 21 U.S.C. 353a, Pharmacy compounding, United States Code (2024 edition); STAT, FDA advisory panel rejects compounding of one peptide, backs another (published July 24, 2026)
labels
research use only
An FDA-approved brand does not make a research-use-only vial of the same molecule an approved product: in a warning letter dated August 24, 2026, FDA found that a seller's "GLP-2 T (Tirzepatide)" was an unapproved new drug because no approved application was in effect for it, although tirzepatide is the active ingredient of the FDA-approved Mounjaro and Zepbound. The letter says that despite labeling that markets the products "for research use only" and "not for human or veterinary use," evidence from the seller's website establishes that they are intended to be drugs for human use.
sources:FDA warning letter to Peptide Partners LLC, MARCS-CMS 735063 (dated August 24, 2026); Mounjaro (tirzepatide) prescribing information, on DailyMed (label effective August 27, 2026); Zepbound (tirzepatide) prescribing information, on DailyMed (label effective August 28, 2026)
sources
the primary documents
Each was opened and checked on October 24, 2026.
- FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, content current as of August 6, 2026
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (introduction), for the meeting of July 23-24, 2026
- Federal Register, 91 FR 20465, Pharmacy Compounding Advisory Committee; Notice of Meeting (document 2026-07361), published April 16, 2026
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, content current as of May 14, 2026
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of April 22, 2026
- FDA warning letter to Peptide Partners LLC, MARCS-CMS 735063, dated August 24, 2026
- 21 U.S.C. 353a, Pharmacy compounding, United States Code, 2024 edition
read next